Chapter 3 Effect of Hormone Replacement Therapy on Inflammatory Biomarkers

Advances in Clinical Chemistry

Volumn 47, Issue , 2009, Pages 59-93

  Georgiadou, Panagiota ^a   Sbarouni, Eftihia ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ANIMAL; CARDIOVASCULAR DISEASE; ESTROGEN THERAPY; FEMALE; HUMAN; INFLAMMATION; MALE; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INFLAMMATION; MALE;

EID: 67651247404     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(09)47003-3     Document Type: Review

References (186)

1. Murray C.J.L., and Lopez A.D. The Global Burden of Disease (1996), World Health Organization, Geneva
2. American Heart Association. Heart Disease and Stroke Statistics-2003 Update (2002), American Heart Association, Dallas, TX
3. AHA Scientific Statement 2004. Evidence-based guidelines for cardiovascular disease prevention in women. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 29-50
4. Vaccarino V., Rathore S.S., Wenger N.K., et al. Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002. N. Engl. J. Med. 353 (2005) 671-682
5. Vaccarino V., Lin Z.Q., Kasl S.V., et al. Sex differences in health status after coronary artery bypass surgery. Circulation 108 (2003) 2642-2647
6. Kannel W.B., and Wilson P.W. Risk factors that attenuate the female coronary disease advantage. Arch. Intern. Med. 155 (1995) 57-61
7. Grodstein F., Stampfer M.J., Manson J.E., et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med. 335 (1996) 453-461
8. Hulley S., Grady D., Bush T., et al. Heart and Estrogen/Progestin Replacement Study (HERS) research group randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
9. Grady D., Herrington D., Bittner V., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 (2002) 49-57
10. Herrington D.M., Reboussin D.M., Brosnihan K.B., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N. Engl. J. Med. 343 (2000) 522-529
11. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
12. Miller A.P., Chen Y.F., Xing D., Feng W., and Oparil S. Hormone replacement therapy and inflammation: interactions in cardiovascular disease. Hypertension 42 (2003) 657-663
13. Blake G.J., and Ridker P.M. Inflammatory bio-markers and cardiovascular risk prediction. J. Intern. Med. 252 (2002) 283-294
14. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
15. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
16. Blake G.J., and Ridker P.M. Novel clinical markers of vascular wall inflammation. Circ. Res. 89 (2001) 763-771
17. Ley K., and Huo Y. VCAM-1 is critical in atherosclerosis. J. Clin. Invest. 107 (2001) 1209-1210
18. Suzuki J., Isobe M., Yamazaki S., Horie S., Okubo Y., and Sekiguchi M. Inhibition of accelerated coronary atherosclerosis with short-term blockade of intercellular adhesion molecule-1 and lymphocyte function associated antigen-1 in a heterotopic murine model of heart transplantation. J. Heart Lung Transplant. 16 (1997) 1141-1148
19. Yasukawa H., Imaizumi T., Matsuoka H., Nakashima A., and Morimatsu M. Inhibition of intimal hyperplasia after balloon injury by antibodies to intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1. Circulation 95 (1997) 1515-1522
20. Nakashima Y., Raines E.W., Plump A.S., Breslow J.L., and Ross R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the apoe-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 842-851
21. Iiyama K., Hajra L., Iiyama M., et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ. Res. 85 (1999) 199-207
22. Sligh Jr. J.E., Ballantyne C.M., Rich S.S., et al. Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1. Proc. Natl. Acad. Sci. USA 90 (1993) 8529-8533
23. Dong Z.M., Chapman S.M., Brown A.A., Frenette P.S., Hynes R.O., and Wagner D.D. The combined role of P- and E-selectins in atherosclerosis. J. Clin. Invest. 102 (1998) 145-152
24. Barron M.K., Lake R.S., Buda A.J., and Tenaglia A.N. Intimal hyperplasia after balloon injury is attenuated by blocking selectins. Circulation 96 (1997) 3587-3592
25. Koskinen P.K., and Lemstrom K.B. Adhesion molecule P-selectin and vascular cell adhesion molecule-1 in enhanced heart allograft arteriosclerosis in the rat. Circulation 95 (1997) 191-196
26. Collins R.G., Velji R., Guevara N.V., Hicks M.J., Chan L., and Beaudet A.L. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J. Exp. Med. 191 (2000) 189-194
27. Frenette P.S., and Wagner D.D. Insights into selectin function from knockout mice. Thromb. Haemost. 78 (1997) 60-64
28. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338 (1998) 436-445
29. Gu L., Okada Y., Clinton S.K., et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell. 2 (1998) 275-281
30. Moyer C.F., Sajuthi D., Tulli H., and Williams J.K. Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. Am. J. Pathol. 138 (1991) 951-960
31. Galea J., Armstrong J., Gadsdon P., Holden H., Francis S.E., and Holt C.M. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 1000-1006
32. Hancock W.W., Adams D.H., Wyner L.R., Sayegh M.H., and Karnovsky M.J. CD4+ mononuclear cells induce cytokine expression, vascular smooth muscle cell proliferation, and arterial occlusion after endothelial injury. Am. J. Pathol. 145 (1994) 1008-1014
33. Mach F., Schonbeck U., and Libby P. CD40 signaling in vascular cells: a key role in atherosclerosis?. Atherosclerosis 137 (1998) S89-S95
34. Schonbeck U., Sukhova G.K., Shimizu K., Mach F., and Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc. Natl. Acad. Sci. USA 97 (2000) 7458-7463
35. Yeh E.T.H., Anderson H.V., Pasceri V., et al. C-reactive protein: linking inflammation to cardiovascular complications. Circulation 104 (2001) 974-975
36. Szmitko P.E., Wang C.H., Weisel R.D., de Almeida J.R., Anderson T.J., and Verma S. New markers of inflammation and endothelial cell activation: part I. Circulation 108 (2003) 1917-1923
37. Buffon A., Biasucci L.M., Liuzzo G., D'Onofrio G., Crea F., and Maseri A. Widespread coronary inflammation in unstable angina. N. Engl. J. Med. 347 (2002) 5-12
38. Willerson J.T., and Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 109 II (2004) 2-10
39. Verma S., Wang C.H., Li S.H., et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106 (2002) 913-919
40. Steinberg D., and Witztum J.L. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis. Circulation 105 (2002) 2107-2111
41. Mackness M.I., Mackness B., and Durrington P.N. Paraoxonase and coronary heart disease. Atheroscler. Suppl. 3 (2002) 49-55
42. Dichtl W., Nilsson L., Goncalves I., et al. Very low-density lipoprotein activates nuclear factor-kappab in endothelial cells. Circ. Res. 84 (1999) 1085-1094
43. Basta G., Lazzerini G., Massaro M., et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105 (2002) 816-822
44. Yamagishi S., Inagaki Y., Okamoto T., et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J. Biol. Chem. 277 (2002) 20309-20315
45. Gualillo O., González-Juanatey J.R., and Lago F. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc. Med. 17 (2007) 275-283
46. Ruiz-Ortega M., Lorenzo O., Ruperez M., Esteban V., Mezzano S., and Egido J. Renin-angiotensin system and renal damage: emerging data on angiotensin II as a proinflammatory mediator. Contrib. Nephrol. 135 (2001) 123-137
47. Costanzo A., Moretti F., Burgio V.L., et al. Endothelial activation by angiotensin II through nfkappab and p38 pathways: involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J. Cell. Physiol. 195 (2003) 402-410
48. Mendelsohn M.E., and Karas R.H. Molecular and cellular basis of cardiovascular gender differences. Science 308 (2005) 1583-1587
49. Mendelsohn M.E., and Karas R.H. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 340 (1999) 1801-1811
50. Bolego C., Vegeto E., Pinna C., Maggi A., and Cignarella A. Selective agonists of estrogen receptor isoforms. New perspectives for cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 2192-2199
51. Chambliss K.L., Yuhanna I.S., Anderson R.G., Mendelsohn M.E., and Shaul P.W. Erbeta has nongenomic action in caveolae. Mol. Endocrinol. 16 (2002) 938-946
52. Chambliss K.L., Yuhanna I.S., Mineo C., et al. Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signalling module in caveolae. Circ. Res. 87 (2000) E44-E52
53. Mendelsohn M.E. Nongenomic, ER-mediated activation of endothelial nitric oxide synthase-how does it work? What does it mean. Circ. Res. 87 (2000) 956-960
54. Chen S.J., Li H., Durand J., Oparil S., and Chen Y.F. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 93 (1996) 577-584
55. Bourassa P.A., Milos P.M., Gaynor B.J., Breslow J.L., and Aiello R.J. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. USA 93 (1996) 10022-10027
56. Foegh M.L., Asotra S., Howell M.H., and Ramwell P.W. Estradiol inhibition of arterial neointimal hyperplasia after balloon injury. J. Vasc. Surg. 19 (1994) 722-726
57. Sullivan Jr. T.R., Karas R.H., Aronovitz M., et al. Estrogen inhibits the response-to-injury in a mouse carotid artery model. J. Clin. Invest. 96 (1995) 2482-2488
58. Sbarouni E., Kyriakides Z.S., and Kremastinos D.T.h. The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. J. Am. Coll. Cardiol. 32 (1998) 1244-1250
59. Sbarouni E., Melissari E., Kyriakides Z.S., and Kremastinos D.T. Effects of simvastatin or hormone replacement therapy, or both, on fibrinogen, factor VII, and plasminogen activator inhibitor levels in postmenopausal women with proven coronary artery disease. Am. J. Cardiol. 86 (2000) 80-83
60. Sbarouni E., Kyriakides Z.S., and Kremastinos D.T. The effect of hormone replacement therapy and simvastatin on plasma homocysteine. J. Womens Health (Larchmt) 14 (2005) 154-158
61. Walsh B.W., Schiff I., Rosner B., Greenberg L., Ravnikar V., and Sacks F.M. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N. Engl. J. Med. 325 (1991) 1196-1204
62. Writing Group for the PEPI Trial Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 273 (1995) 199-208
63. Gol M., Akan P., Dogan E., Karas C., Saygili U., and Posaci C. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Maturitas 53 (2006) 252-259
64. Hu P., Greendale G.A., Palla S.L., et al. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the Postmenopausal Estrogen Progestin Intervention (PEPI) trial. Atherosclerosis 185 (2006) 347-352
65. Koh K.K., Shin M.S., Sakuma I., et al. Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1516-1521
66. Mosca L. The role of hormone replacement therapy in the prevention of postmenopausal heart disease. Arch. Intern. Med. 160 (2000) 2263-2272
67. Langer R.D., Pradhan A.D., Lewis C.E., et al. Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease: the Women's Health Initiative Observational Study. Thromb. Haemost. 93 (2005) 1108-1116
68. Pradhan A.D., Manson J.E., Rossouw J.E., et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease prospective analysis from the Women's Health Initiative observational study. JAMA 288 (2002) 980-987
69. Morello K.C., Wurz G.T., and DeGregorio M.W. SERMs: current status and future trends. Crit. Rev. Oncol. Hematol. 43 (2002) 63-76
70. Riggs L., and Hartmann L. Selective estrogen receptors modulators-Mechanisms of action and application to clinical practice. N. Engl. J. Med. 348 (2003) 618-629
71. Paech K., Webb P., Kuiper G.G., et al. Differential ligand activation of estrogen receptors Eralpha and Erbeta at AP1 sites. Science 277 (1997) 1508-1510
72. Jones P.S., Parrott E., and White I.N. Activation of transcription by estrogen receptor alpha and beta is cell type- and promoter-dependent. J. Biol. Chem. 274 (1999) 32008-32014
73. Carlquist M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 18 (1999) 4608-4618
74. Kurebayashi J., Otsuki T., Kunisue H., Tanaka K., Yamamoto S., and Sonoo H. Expression levels of estrogen receptor alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin. Cancer. Res. 6 (2000) 512-518
75. Webb P., Lopez G.N., Uht R.M., and Kushner P.J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol. 9 (1995) 443-456
76. Pace P., Jarman M., Phillips D., Hewer A., Bliss J., and Coombes R.C. Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts. Br. J. Cancer. 76 (1997) 700-704
77. DeGregorio M.W., Wurz G.T., Taras T.L., Erkkola R.U., Halonen K.H., and Huupponen R.K. Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. Eur. J. Clin. Pharmacol. 56 (2000) 469-475
78. Walsh B.W., Kuller L.H., Wild R.A., et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279 (1998) 1445-1451
79. Saarto T., Blomqvist C., Ehnholm C., Taskinen M.R., and Elomaa I. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J. Clin. Oncol. 14 (1996) 429-433
80. Sbarouni E., Flevari P., Kroupis C., Kyriakides Z.S., Koniavitou K., and Kremastinos D.T. The effects of raloxifene and simvastatin on plasma lipids and endothelium. Cardiovasc. Drugs. Ther. 17 (2003) 319-323
81. Ylikorkala O., Cacciatore B., Halonen K., et al. Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women. Menopause 10 (2003) 440-447
82. Kauffman R.F., Bean J.S., Fahey K.J., Cullinan G.J., Cox D.A., and Bensch W.R. Raloxifene and estrogen inhibit neointimal thickening after balloon injury in the carotid artery of male and ovariectomized female rats. J. Cardiovasc. Pharmacol. 36 (2000) 459-465
83. Williams J.K., Wagner J.D., Li Z., Golden D.L., and Adams M.R. Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 403-408
84. Clarkson T.B., Anthony M.S., and Jerome C.P. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J. Clin. Endocrinol. Metab. 83 (1998) 721-726
85. Castelo-Branco C., Sanjuan A., Casals E., et al. Raloxifene inhibits cholesterol aortic content but not atherosclerotic plaque size in oophorectomised cholesterol-fed rabbits. J. Obstet. Gynaecol. 24 (2004) 47-51
86. Bradbury B.D., Lash T.L., Kaye J.A., and Jick S.S. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly diagnosed angina. Cancer 103 (2005) 1114-1121
87. Grainger D.J., and Schofield P.M. Tamoxifen for the prevention of myocardial infarction in humans. Preclinical and early clinical evidence. Circulation 112 (2005) 3018-3024
88. Barrett-Connor E., Grady D., Sashegyi A., et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287 (2002) 847-857
89. Barrett-Connor E., Mosca L., Collins P., et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355 (2006) 125-137
90. Albertazzi P., and Purdie D. The nature and utility of the phytoestrogens: a review of the evidence. Maturitas 42 (2002) 173-185
91. Kris-Etherton P.M., Hecker K.D., Bonanome A., et al. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am. J. Med. 113 (2002) 71S-88S
92. Adlercreutz H., and Mazur W. Phyto-oestrogens and Western diseases. Ann. Med. 29 (1997) 95-120
93. Kuiper G.G., Lemmen J.G., Carlsson B., et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139 (1998) 4252-4263
94. Lee G.S., Choi K.C., Kim H.J., and Jeung E.B. Effect of genistein as a selective estrogen receptor beta agonist on the expression of Calbindin-D9k in the uterus of immature rats. Toxicol. Sci. 82 (2004) 451-457
95. Akiyama T., Ishida J., Nakagawa S., et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262 (1987) 5592-5595
96. Marsh J. Phytoestrogens and vascular therapy. J. Am. Coll. Cardiol. 35 (2000) 1986-1987
97. Anthony M.S., Clarkson T.B., and Williams J.K. Effects of soy isoflavones on atherosclerosis: potential mechanisms. Am. J. Clin. Nutr. 68 (1998) 1390S-1393S
98. Barnes S. Soy isoflavones: phytoestrogens and what else?. J. Nutr. 134 (2004) 1225S-1228S
99. Somekawa Y., Chiguchi M., Ishibashi T., and Aso T. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet. Gynecol. 97 (2001) 109-115
100. Anderson J.W., Johnstone B.M., and Cook-Newell M.E. Meta-analysis of the effects of soy protein intake on serum lipids. N. Engl. J. Med. 333 (1995) 276-282
101. Alexandersen P., Haarbo J., Breinholt V., and Christiansen C. Dietary phytoestrogens and estrogen inhibit experimental atherosclerosis. Climacteric 4 (2001) 151-159
102. Anthony M.S., Clarkson T.B., Hughes Jr. C.L., Morgan T.M., and Burke G.L. Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal rhesus monkeys. J. Nutr. 126 (1996) 43-50
103. Yamakoshi J., Piskula M.K., Izumi T., et al. Isoflavone aglycone-rich extract without soy protein attenuates atherosclerosis development in cholesterol-fed rabbits. J. Nutr. 130 (2000) 1887-1893
104. Figtree G.A., Griffiths H., Lu Y.Q., Webb C.M., MacLeod K., and Collins P. Plant-derived estrogens relax coronary arteries in vitro by a calcium antagonistic mechanism. J. Am. Coll. Cardiol. 35 (2000) 1977-1985
105. Jenkins D.J., Kendall C.W., Garsetti M., et al. Effect of soy protein foods on low-density lipoprotein oxidation and ex vivo sex hormone receptor activity-a controlled crossover trial. Metabolism 49 (2000) 537-543
106. Van der Schouw Y.T., Kreijkamp-Kaspers S., Peeters P.H., Keinan-Boker L., Rimm E.B., and Grobbee D.E. Prospective study on usual dietary phytoestrogens intake and cardiovascular disease in Western women. Circulation 111 (2005) 465-471
107. Sbarouni E., Iliodromitis E.K., Zoga A., Theodorakis G.N., and Kremastinos D.T. The effect of the phytoestrogen genistein on myocardial protection and preconditioning in hypercholesterolemia. Cardiovasc. Drugs. Ther. 21 (2007) 399-400
108. Sbarouni E., Iliodromitis E.K., Zoga A., Vlachou G., Andreadou I., and Kremastinos D.T. The effect of the phytoestrogen genistein on myocardial protection, preconditioning and oxidative stress. Cardiovasc. Drugs. Ther. 20 (2006) 253-258
109. Lichtenstein A.H., Jalbert S.M., Adlercreutz H., et al. Lipoprotein response to diets high in soy or animal protein with and without isoflavones in moderately hypercholesterolemic subjects. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1852-1858
110. Simons L.A., von Konigsmark M., Simons J., and Celermajer D.S. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am. J. Cardiol. 85 (2000) 1297-1301
111. Sacks F.M. Dietary phytoestrogens to prevent cardiovascular disease: early promise unfulfilled. Circulation 111 (2005) 385-387
112. Li X., and O'Malley B.W. Unfolding the action of progesterone receptors. J. Biol. Chem. 278 (2003) 39261-39264
113. Khalil R.A. Sex hormones as potential modulators of vascular function in hypertension. Hypertension 46 (2005) 249-254
114. Barbagallo M., Dominguez L.J., Licata G., et al. Vascular effects of progesterone: role of cellular calcium regulation. Hypertension 37 (2001) 142-147
115. Horowitz K.B., and Horowitz L.D. Canine vascular tissues are targets for androgens, estrogens, progestins and glucocorticoids. J. Clin. Invest. 69 (1982) 750-758
116. Gerhard M., Walsh B.W., Tawakol A., et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 98 (1998) 1158-1163
117. Spritzer P.M., Vitola D., Vilodre L.C., et al. One year follow-up of hormone replacement therapy with percutaneous estradiol and low-dose vaginal natural progesterone in women with mild to moderate hypertension. Exp. Clin. Endocrinol. Diabetes 111 (2003) 267-273
118. Sbarouni E., Iliodromitis E.K., Bofilis E., Kyriakides Z.S., and Kremastinos D.T. Estrogen alone or combined with medroxyprogesterone but not raloxifene reduce myocardial infarct size. Eur. J. Pharmacol. 467 (2003) 163-168
119. Rosano G.M., Vitale C., Silvestri A., and Fini M. Metabolic and vascular effect of progestins in post-menopausal women. Implications for cardioprotection. Maturitas 46 (2003) S17-S29
120. White W.B., Hanes V., Chauhan V., and Pitt B. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension 48 (2006) 246-253
121. Hu P., Greendale G.A., Palla S.C., et al. The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the Postmenopausal Estrogen Progestin Intervention (PEPI) trial. Atherosclerosis 185 (2006) 347-352
122. Sanada M., Higashi Y., Nakagawa K., et al. Combination therapy of low-dose medroxyprogesterone acetate and oral estrogen does not affect endothelial function in the forearms of postmenopausal women. Menopause 9 (2002) 360-366
123. Wakatsuki A., Okatani Y., Ikenoue N., and Fukaya T. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation 104 (2001) 1773-1778
124. Ridker P. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (2003) 363-369
125. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342 (2000) 836-843
126. Haverkate F., Thompson S.G., Pyke S.D., et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 349 (1997) 462-466
127. Ridker P.M., Rifai N., Clearfield M., et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344 (2001) 1959-1965
128. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., and Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) investigators. Circulation 100 (1999) 230-235
129. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350 (2004) 1387-1397
130. Tall A.R. C-reactive protein reassessed. N. Engl. J. Med. 350 (2004) 1450-1452
131. Silvestri A., Gebara O., Vitale C., et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 107 (2003) 3165-3169
132. Cushman M., Legault C., Barrett-Connor E., et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation 100 (1999) 717-722
133. Herrington D.M., Howard T.D., Hawkins G.A., et al. Estrogen receptor polymorphisms and effects of estrogen replacement on HDL cholesterol in women with coronary disease. N. Engl. J. Med. 346 (2002) 967-975
134. Wakatsuki A., Okatani Y., Ikenoue N., and Fukaya T. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation 105 (2002) 1436-1439
135. Djurovic S., Os I., Hofstad A.E., Abdelnoor M., Westheim A., and Berg K. Increased plasma concentrations of TGF-beta1 after hormone replacement therapy. J. Intern. Med. 247 (2000) 279-285
136. Sattar N., Perera M., Small M., et al. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes. Lancet 354 (1999) 487-488
137. Decensi A., Omodei U., Robertson C., et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 106 (2002) 1224-1228
138. Vongpatanasin W., Tuncel M., Wang Z., Arbique D., Mehrad B., and Jialal I. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J. Am. Coll. Cardiol. 41 (2003) 1358-1363
139. Herrington D.M., Howard T.D., Brosnihan K.B., et al. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 105 (2002) 1879-1882
140. Sbarouni E., Kyriakides Z.S., and Kremastinos D.T. Effect of simvastatin on serum C-reactive protein during hormone replacement therapy. Am. J. Cardiol. 93 (2004) 217-218
141. Koh K.K., Schenke W.H., Waclawiw M.A., Csako G., and Cannon III R.O. Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women. Circulation 105 (2002) 1531-1533
142. Blum A., Schenke W.H., Hathaway L., et al. Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women. Am. J. Cardiol. 86 (2000) 892-895
143. de Valk-de Roo G.W., Stehouwer C.D., Meijer P., et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 2993-3000
144. Walsh B.W., Paul S., Wild R.A., et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial. J. Clin. Endocrinol. Metab. 85 (2000) 214-218
145. Bonanni B., Johansson H., Gandini S., et al. Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women. J. Thromb. Haemost. 1 (2003) 2149-2152
146. Vogelvang T.E., Mijatovic V., Kenemans P., Schalkwijk C.G., and van der Mooren M.J. Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women. Am. J. Cardiol. 94 (2004) 1205-1208
147. Nikander E., Metsa-Heikkila M., Tiitinen A., and Ylikorkala O. Evidence of a lack of effect of a phytoestrogen regimen on the levels of C-reactive protein, E-selectin, and nitrate in postmenopausal women. J. Clin. Endocrinol. Metab. 88 (2003) 5180-5185
148. Hall W.L., Vafeiadou K., Hallund J., et al. Soy-isoflavone-enriched foods and markers of lipid and glucose metabolism in postmenopausal women: interactions with genotype and equol production. Am. J. Clin. Nutr. 83 (2006) 592-600
149. Liang J.S., Schreiber B.M., Salmona M., Phillip G., Gonnerman W.A., de Beer F.C., et al. Amino terminal region of acute phase, but not constitutive, serum amyloid A (aposaa) specifically binds and transports cholesterol into aortic smooth muscle and hepg2 cells. J. Lipid. Res. 37 (1996) 2109-2116
150. Navab M., Berliner J.A., Subbanagounder G., et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 481-488
151. Goudev A., Georgiev D.B., Koycheva N., Manasiev N., and Kyurkchiev S. Effects of low dose hormone replacement therapy on markers of inflammation in postmenopausal women. Maturitas 43 (2002) 49-53
152. Zegura B., Guzic-Salobir B., Sebestjen M., and Keber I. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause 13 (2006) 643-650
153. Abbas A., Fadel P.J., Wang Z., Arbique D., Jialal I., and Vongpatanasin W. Contrasting effects of oral versus transdermal estrogen on serum amyloid A (SAA) and high-density lipoprotein-SAA in postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 24 (2004) e164-e167
154. Jenkins D.J., Kendall C.W., Connelly P.W., et al. Effects of high- and low-isoflavone (phytoestrogen) soy foods on inflammatory biomarkers and proinflammatory cytokines in middle-aged men and women. Metabolism 51 (2002) 919-924
155. Pigott R., Dillon L.P., Hemingway I.H., et al. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem. Biophys. Res. Commun. 187 (1992) 584-589
156. Haught W.H., Mansour M., Rothlein R., et al. Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischemic heart disease. Am. Heart. J. 1321 (1996) 1-8
157. Hwang S.J., Ballantyne C.M., Sharrett A.R., et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96 (1997) 4219-4225
158. Blankenberg S., Rupprecht H.J., Bickel C., et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 104 (2001) 1336-1342
159. Ridker P.M., Hennekens C.H., Roitman-Johnson B., Stampfer M.J., and Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351 (1998) 88-92
160. Caulin-Glaser T., Farrell W.J., Pfau S.E., et al. Modulation of circulating cellular adhesion molecules in postmenopausal women with coronary artery disease. J. Am. Coll. Cardiol. 31 (1998) 1555-1560
161. Störk S., von Schacky C., and Angerer P. The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial. Atherosclerosis 165 (2002) 301-307
162. van Baal W.M., Emeis J.J., Kenemans P., et al. Short-term hormone replacement therapy: reduced plasma levels of serum adhesion molecules. Eur. J. Clin. Invest. 29 (1999) 913-921
163. Zanger D., Yang B.K., Ardans J., et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J. Am. Coll. Cardiol. 36 (2000) 1797-1802
164. Koh K.K., Jin D.K., Yang S.H., et al. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 103 (2001) 1961-1966
165. Otsuki M., Saito H., Xu X., et al. Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 243-248
166. Koh K., and Yoon B. Controversies regarding hormone therapy: insights from inflammation and hemostasis. Cardiovasc. Res. 70 (2006) 22-30
167. Koh K.K., Cardillo C., Bui M.N., et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 99 (1999) 354-360
168. Sbarouni E., Flevari P., Kroupis C., Kyriakides Z.S., Koniavitou K., and Kremastinos D.T. The effects of raloxifene and simvastatin on plasma lipids and endothelium. Cardiovasc. Drugs. Ther. 17 (2003) 319-323
169. Vafeiadou K., Hall W.L., and Williams C.M. Does genotype and equol-production status affect response to isoflavones? Data from a pan-European study on the effects of isoflavones on cardiovascular risk markers in post-menopausal women. Proc. Nutr. Soc. 65 (2006) 106-115
170. Ridker P.M., Buring J.E., and Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 103 (2001) 491-495
171. Koh K.K., Ahn J.Y., Kang M.H., et al. Effects of hormone replacement therapy on plaque stability, inflammation, and fibrinolysis in hypertensive or overweight postmenopausal women. Am. J. Cardiol. 88 (2001) 1423-1426
172. Wakatsuki A., Ikenoue N., Shinohara K., Watanabe K., and Fukaya T. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 571-576
173. Sumino H., Ichikawa S., Kasama S., et al. Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women. Hypertens. Res. 28 (2005) 579-584
174. Blum A., Lang N., Peleg A., et al. Effects of oral soy protein on markers of inflammation in postmenopausal women with mild hypercholesterolemia. Am. Heart. J. 145 (2003) e7
175. Ridker P.M., Rifai N., Stampfer M.J., and Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000) 1767-1772
176. Lindmark E., Diderholm E., Wallentin L., and Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 286 (2001) 2107-2113
177. Walsh B.W., Cox D.A., Sashegyi A., et al. Role of tumor necrosis factor-α and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am. J. Cardiol. 88 (2001) 825-828
178. Herrington D.M., Brosnihan K.B., Pusser B.E., et al. Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J. Clin. Endocrinol. Metab. 86 (2001) 4216-4222
179. Tankó L.B., and Christiansen C. Adipose tissue, insulin resistance and low-grade inflammation: Implications for atherogenesis and the cardiovascular harm of estrogen plus progestogen therapy. Climacteric 9 (2006) 169-180
180. Reckless J., Rubin E.M., Verstuyft J.B., et al. Monocyte chemoattractant protein-1 but not tumor necrosis factor-α is correlated with monocyte infiltration in mouse lipid lesions. Circulation 99 (1999) 2310-2316
181. Pervin S., Singh R., Rosenfeld M.E., et al. Estradiol suppresses MCP-1 expression in vivo: implications for atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1575-1582
182. Soejima H., Ogawa H., Yasue H., et al. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. J. Am. Coll. Cardiol. 34 (1999) 983-988
183. Koh K.K., Son J.W., Ahn J.Y., et al. Effect of hormone replacement therapy on nitric oxide bioactivity and monocyte chemoattractant protein-1 levels. Int. J. Cardiol. 81 (2001) 43-50
184. Skoog T., Dichtl W., Boquist S., et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur. Heart. J. 23 (2002) 376-383
185. Ridker P.M., Rifai N., Pfeffer M., Sacks F., Lepage S., and Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 101 (2000) 2149-2153
186. Brooks-Asplund E.M., Tupper C.E., Daun J.M., Kenney W.L., and Cannon J.G. Hormonal modulation of interleukin-6, tumor necrosis factor and associated receptor secretion in postmenopausal women. Cytokine 19 (2002) 193-200